Johnson & Johnson (JNJ) shareholders
Close on Nov 19, 2026Market cap $643.09BP/E 40.5Yield 1.92%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 186,308,341 | 7.70% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 180,631,228 | 7.49% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | – | 5.52% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of JNJ | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 212,098,264 | 8.81% | $53.87B | −1,287,282 | 0.80% |
| Vanguard Capital Management LLC | 157,226,374 | 6.53% | $39.93B | +621,004 | 0.85% |
| State Street Corp | 133,776,025 | 5.56% | $33.98B | +299,737 | 1.01% |
| Vanguard Portfolio Management LLC | 64,370,816 | 2.67% | $16.35B | +856,380 | 0.74% |
| Geode Capital Management, LLC | 59,086,417 | 2.45% | $14.97B | −78,445 | 0.80% |
| JPMorgan Chase & Co | 58,301,609 | 2.42% | $15.07B | −4,794,735 | 0.83% |
| Morgan Stanley | 44,808,254 | 1.86% | $11.38B | +87,087 | 0.60% |
| Norges Bank | 31,825,084 | 1.32% | $8.08B | New | 0.81% |
| State Farm Mutual Automobile Insurance Co | 31,590,952 | 1.31% | $8.02B | – | 5.49% |
| Northern Trust Corp | 28,792,064 | 1.20% | $7.31B | −527,605 | 0.85% |
| Bank Of America Corp /De/ | 23,438,141 | 0.97% | $5.95B | −2,078,556 | 0.38% |
| Price T Rowe Associates Inc /Md/ | 22,996,878 | 0.96% | $5.84B | +6,505,745 | 0.58% |
| FMR LLC | 22,595,566 | 0.94% | $5.74B | −2,176,262 | 0.25% |
| Wellington Management Group Llp | 22,588,696 | 0.94% | $5.74B | +2,513,321 | 0.99% |
| Bank of New York Mellon Corp | 21,683,347 | 0.90% | $5.51B | −138,615 | 0.90% |
| Goldman Sachs Group Inc | 19,722,544 | 0.82% | $5.01B | +1,665,497 | 0.43% |
| Legal & General Group Plc | 19,286,904 | 0.80% | $4.90B | −60,958 | 1.02% |
| Charles Schwab Investment Management Inc | 19,126,165 | 0.79% | $4.86B | −51,054 | 0.65% |
| UBS Asset Management Americas Inc | 18,416,123 | 0.77% | $4.68B | −1,211,990 | 0.85% |
| Wells Fargo & Company/Mn | 17,374,433 | 0.72% | $4.41B | +448,979 | 0.71% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4,673 | 1.80B | 74.8% | 222 / 2052 | 1908 / 119 | 103M | 61M |
| Q1 2026 | 4,647 | 1.78B | 73.8% | 302 / 1712 | 2161 / 124 | 344M | 113M |
| Q4 2025 | 4,539 | 1.79B | 74.4% | 543 / 1654 | 1935 / 106 | 129M | 129M |
| Q3 2025 | 4,196 | 1.80B | 74.7% | 295 / 1704 | 1800 / 120 | 134M | 105M |
| Q2 2025 | 4,092 | 1.77B | 73.6% | 176 / 1635 | 1889 / 181 | 81M | 50M |
| Q1 2025 | 4,157 | 1.74B | 72.5% | 255 / 1707 | 1842 / 147 | 92M | 77M |
| Q4 2024 | 4,112 | 1.74B | 72.3% | 470 / 1357 | 1937 / 177 | 93M | 95M |
| Q3 2024 | 3,891 | 1.76B | 72.9% | 230 / 1559 | 1735 / 104 | 267M | 48M |
| Q2 2024 | 3,811 | 1.74B | 72.2% | 161 / 1517 | 1791 / 153 | 84M | 137M |
| Q1 2024 | 3,857 | 1.80B | 74.8% | 163 / 1573 | 1752 / 128 | 109M | 54M |
| Q4 2023 | 3,875 | 1.75B | 72.6% | 378 / 1303 | 1881 / 126 | 133M | 49M |
| Q3 2023 | 3,684 | 1.67B | 69.3% | 151 / 1222 | 2004 / 181 | 29M | 175M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
1,504 funds held JNJ in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of JNJ | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 76,421,624 | 3.17% | $19.41B | 0.84% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 62,378,802 | 2.59% | $15.84B | 0.95% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 33,111,750 | 1.38% | $8.41B | 0.95% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 30,839,534 | 1.28% | $6.95B | 0.84% | May 31, 2026 |
| Vanguard Value Index Fund | 22,911,023 | 0.95% | $5.82B | 2.29% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 17,006,170 | 0.71% | $4.32B | 10.64% | Jun 30, 2026 |
| Vanguard Dividend Appreciation Index Fund | 13,619,903 | 0.57% | $3.49B | 2.67% | Jul 31, 2026 |
| Vanguard Institutional Index Fund | 13,067,915 | 0.54% | $3.32B | 0.95% | Jun 30, 2026 |
| Vanguard High Dividend Yield Index Fund | 9,702,127 | 0.40% | $2.49B | 2.51% | Jul 31, 2026 |
| Washington Mutual Investors Fund | 9,490,561 | 0.39% | $2.43B | 1.12% | Jul 31, 2026 |
| Vanguard Health Care Fund | 7,191,566 | 0.30% | $1.84B | 4.83% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 7,135,556 | 0.30% | $1.61B | 8.47% | May 31, 2026 |
| Columbia Dividend Income Fund | 7,113,980 | 0.30% | $1.60B | 3.40% | May 31, 2026 |
| JPMorgan Large Cap Growth Fund | 6,791,600 | 0.28% | $1.72B | 1.42% | Jun 30, 2026 |
| MFS Value Fund | 6,243,503 | 0.26% | $1.41B | 2.75% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joaquin Duato | CEO and Chairman of the Board, Director | 307,837 | 0.01% | Aug 14, 2026 |
| Elizabeth Forminard | EVP, Chief Legal Officer | 16,994 | 0.00% | Nov 13, 2026 |
| Timothy Schmid | EVP, WW Chair, MedTech | 48,778 | 0.00% | Sep 4, 2026 |
| Thomas Cavanaugh | EVP WW Chair, Innovative Med. | 499 | 0.00% | Sep 1, 2026 |
| Jennifer L. Taubert | EVP, WWC. Innovative Medicine | 209,451 | 0.01% | Aug 18, 2026 |
| Vanessa Broadhurst | EVP, Global Corp Affairs | 23,003 | 0.00% | Jul 21, 2026 |
| Kathryn E. Wengel | EVP, Chief TO and Risk Officer | 124,659 | 0.01% | Jun 12, 2026 |
| John C. Reed | EVP, Innovative Medicine, R&D | 35,913 | 0.00% | May 4, 2026 |
| Robert J. Decker | VP Corporate Controller | 28,537 | 0.00% | Mar 3, 2026 |
| Joseph J. Wolk | Exec VP, CFO | 109,969 | 0.00% | Feb 18, 2026 |
| James D. Swanson | EVP, CIO | 46,219 | 0.00% | Feb 18, 2026 |
| Kristen Mulholland | EVP, Chief HR Officer | 19,678 | 0.00% | Feb 18, 2026 |
| Eugene A. Woods | Director | 250 | 0.00% | Sep 10, 2026 |
| Marillyn A. Hewson | Director | 3,000 | 0.00% | Sep 10, 2026 |
| Daniel E. Pinto | Director | 0 | – | Sep 10, 2026 |
| John G. Morikis | Director | 1,849 | 0.00% | Apr 27, 2026 |
| Hubert Joly | Director | 5,000 | 0.00% | Apr 27, 2026 |
| Mark B. McClellan | Director | – | – | Apr 27, 2026 |
| Mary C. Beckerle | Director | – | – | Apr 27, 2026 |
| Mark A. Weinberger | Director | 1,000 | 0.00% | Apr 27, 2026 |
| Paula A. Johnson | Director | 191 | 0.00% | Apr 27, 2026 |
| Nadja West | Director | – | – | Apr 27, 2026 |
| Jennifer A. Doudna | Director | – | – | Apr 27, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Elizabeth Forminard EVP, Chief Legal Officer | Nov 12, 2026 | Sale | −13,072 | $284.39 | $3.72M | 16,994 |
| Elizabeth Forminard EVP, Chief Legal Officer | Nov 12, 2026 | Option exercise | +13,072 | $151.41 | $1.98M | 30,066 |
| Timothy Schmid EVP, WW Chair, MedTech | Sep 2, 2026 | Option exercise | +22,527 | $151.41 | $3.41M | 47,974 |
| Timothy Schmid EVP, WW Chair, MedTech | Sep 2, 2026 | Option exercise | +11,070 | $131.94 | $1.46M | 36,517 |
| Timothy Schmid EVP, WW Chair, MedTech | Sep 2, 2026 | Sale | −11,070 | $274.74 | $3.04M | 25,447 |
| Timothy Schmid EVP, WW Chair, MedTech | Sep 2, 2026 | Sale | −22,527 | $274.74 | $6.19M | 25,447 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Aug 17, 2026 | Option exercise | +15,000 | $115.67 | $1.74M | 209,451 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Aug 17, 2026 | Sale | −15,000 | $263.36 | $3.95M | 194,451 |
| Joaquin Duato CEO and Chairman of the Board, Director | Aug 13, 2026 | Sale | −102,315 | $261.00 | $26.70M | 275,967 |
| Joaquin Duato CEO and Chairman of the Board, Director | Aug 13, 2026 | Option exercise | +123,291 | $115.67 | $14.26M | 399,258 |
| Joaquin Duato CEO and Chairman of the Board, Director | Aug 13, 2026 | Sale | −20,976 | $262.00 | $5.50M | 378,282 |
| Elizabeth Forminard EVP, Chief Legal Officer | Aug 6, 2026 | Sale | −9,344 | $257.76 | $2.41M | 23,568 |
| Elizabeth Forminard EVP, Chief Legal Officer | Aug 6, 2026 | Option exercise | +9,344 | $131.94 | $1.23M | 32,912 |
| Elizabeth Forminard EVP, Chief Legal Officer | Aug 6, 2026 | Sale | −6,574 | $255.93 | $1.68M | 16,994 |
| Joaquin Duato CEO and Chairman of the Board, Director | Aug 5, 2026 | Sale | −6,523 | $258.74 | $1.69M | 275,967 |
| Joaquin Duato CEO and Chairman of the Board, Director | Aug 5, 2026 | Sale | −41,957 | $258.06 | $10.83M | 282,490 |
| Vanessa Broadhurst EVP, Global Corp Affairs | Jul 20, 2026 | Sale | −23,054 | $251.27 | $5.79M | 23,003 |
| Vanessa Broadhurst EVP, Global Corp Affairs | Jul 20, 2026 | Option exercise | +11,925 | $131.94 | $1.57M | 46,057 |
| Vanessa Broadhurst EVP, Global Corp Affairs | Jul 20, 2026 | Option exercise | +11,129 | $129.51 | $1.44M | 34,132 |
| Kathryn E. Wengel EVP, Chief TO and Risk Officer | Jun 11, 2026 | Option exercise | +10,000 | $115.67 | $1.16M | 124,288 |
| Kathryn E. Wengel EVP, Chief TO and Risk Officer | Jun 11, 2026 | Sale | −10,000 | $241.15 | $2.41M | 114,288 |
| John C. Reed EVP, Innovative Medicine, R&D | May 1, 2026 | Option exercise | +25,255 | – | – | 35,913 |
| John C. Reed EVP, Innovative Medicine, R&D | May 1, 2026 | Tax withholding | −11,002 | $229.85 | $2.53M | 24,911 |
| Robert J. Decker VP Corporate Controller | Feb 27, 2026 | Option exercise | +4,075 | $115.67 | $471.36K | 27,757 |
| Robert J. Decker VP Corporate Controller | Feb 27, 2026 | Sale | −4,075 | $247.87 | $1.01M | 23,682 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 20, 2026 | Sale | −1,322 | $245.66 | $324.76K | 25,447 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 18, 2026 | Option exercise | +13,625 | $115.67 | $1.58M | 40,394 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 18, 2026 | Sale | −13,625 | $244.20 | $3.33M | 26,769 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 18, 2026 | Option exercise | +8,998 | $129.51 | $1.17M | 35,767 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 18, 2026 | Sale | −8,998 | $244.53 | $2.20M | 26,769 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 17, 2026 | Option exercise | +21,721 | $157.92 | $3.43M | 34,662 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 17, 2026 | Sale | −21,721 | $243.00 | $5.28M | 12,941 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 17, 2026 | Sale | −2,283 | $243.00 | $554.77K | 10,658 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 17, 2026 | Sale | −29,927 | $243.00 | $7.27M | 12,941 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 17, 2026 | Option exercise | +29,927 | $156.15 | $4.67M | 42,868 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Sale | −12,066 | $242.87 | $2.93M | 38,961 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Option exercise | +33,386 | $131.94 | $4.40M | 72,347 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Sale | −33,386 | $242.75 | $8.10M | 38,961 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Sale | −24,961 | $242.68 | $6.06M | 14,000 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Sale | −19,241 | $242.99 | $4.68M | 38,961 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Option exercise | +19,241 | $115.67 | $2.23M | 58,202 |
| Joseph J. Wolk Exec VP, CFO | Feb 17, 2026 | Option exercise | +12,066 | $129.51 | $1.56M | 51,027 |
| Vanessa Broadhurst EVP, Global Corp Affairs | Feb 17, 2026 | Sale | −6,197 | $243.39 | $1.51M | 23,003 |
| James D. Swanson EVP, CIO | Feb 17, 2026 | Option exercise | +20,521 | $164.62 | $3.38M | 46,219 |
| James D. Swanson EVP, CIO | Feb 17, 2026 | Sale | −20,521 | $242.70 | $4.98M | 25,698 |
| Elizabeth Forminard EVP, Chief Legal Officer | Feb 15, 2026 | Option exercise | +961 | – | – | 23,541 |
| Elizabeth Forminard EVP, Chief Legal Officer | Feb 15, 2026 | Tax withholding | −492 | $243.45 | $119.78K | 23,049 |
| Elizabeth Forminard EVP, Chief Legal Officer | Feb 15, 2026 | Option exercise | +1,063 | – | – | 24,112 |
| Elizabeth Forminard EVP, Chief Legal Officer | Feb 15, 2026 | Tax withholding | −544 | $243.45 | $132.44K | 23,568 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 15, 2026 | Tax withholding | −385 | $243.45 | $93.73K | 11,622 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 15, 2026 | Tax withholding | −528 | $243.45 | $128.54K | 12,941 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 15, 2026 | Option exercise | +1,847 | – | – | 13,469 |
| John C. Reed EVP, Innovative Medicine, R&D | Feb 15, 2026 | Option exercise | +1,349 | – | – | 12,007 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Feb 15, 2026 | Tax withholding | −945 | $243.45 | $230.06K | 194,451 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Feb 15, 2026 | Option exercise | +1,847 | – | – | 195,396 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Feb 15, 2026 | Tax withholding | −816 | $243.45 | $198.66K | 193,549 |
| Jennifer L. Taubert EVP, WWC. Innovative Medicine | Feb 15, 2026 | Option exercise | +1,594 | – | – | 194,365 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 15, 2026 | Option exercise | +1,028 | – | – | 26,206 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 15, 2026 | Tax withholding | −15 | $243.45 | $3.65K | 26,191 |
| Timothy Schmid EVP, WW Chair, MedTech | Feb 15, 2026 | Option exercise | +1,026 | – | – | 27,217 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Johnson & Johnson's stock actually held short. Settlement fails (shares not delivered on time) peaked at 89,357 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Timothy Schmid Officer | Sep 2, 2026 | 33,597 | $9.23M | Sep 2, 2026 | Stock Option Exercise |
| Jennifer L. Taubert Officer | Aug 17, 2026 | 15,000 | $3.95M | Aug 17, 2026 | Stock Option Exercise |
| Joaquin Duato Officer, Director | Aug 13, 2026 | 123,291 | $32.20M | Aug 13, 2026 | Stock Option Exercise |
| Elizabeth Forminard Officer | Aug 6, 2026 | 15,918 | $4.09M | Aug 6, 2026 | Stock Option Exercise |
| Joaquin Duato CEO, Chariman | Aug 5, 2026 | 48,480 | $12.36M | Aug 5, 2026 | Executive compensation |
| Vanessa Broadhurst Officer | Jul 20, 2026 | 23,054 | $5.79M | Jul 20, 2026 | Stock Option Exercise |
| Kathryn E. Wengel Officer | Jun 11, 2026 | 10,000 | $2.40M | Jun 11, 2026 | Stock Option Exercise |
| Robert J. Decker Officer | Feb 27, 2026 | 4,075 | $1.01M | Feb 27, 2026 | Option Granted - 02/13/2017 |
| Timothy Schmid Officer | Feb 20, 2026 | 1,322 | $324.76K | Feb 20, 2026 | Restricted Stock Vesting |
| Timothy Schmid Officer | Feb 18, 2026 | 22,623 | $5.53M | Feb 18, 2026 | Option Granted - 02/13/2017 |
| Vanessa Broadhurst Officer | Feb 17, 2026 | 6,197 | $1.51M | Feb 17, 2026 | Restricted Stock Vesting |
| James D. Swanson Officer | Feb 17, 2026 | 20,521 | $4.98M | Feb 17, 2026 | Options Granted - 02/08/2021 |
| Joseph J. Wolk Officer | Feb 17, 2026 | 89,654 | $21.77M | Feb 17, 2026 | Restricted Stock Vesting |
| John C. Reed Officer | Feb 17, 2026 | 53,931 | $13.11M | Feb 17, 2026 | Restricted Stock Vesting |
| James D. Swanson Officer | Feb 13, 2026 | 41,559 | $10.13M | Feb 13, 2026 | Option Granted - 02/14/2022 |
Congress trades
40 trades in Johnson & Johnson reported by 14 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Thomas H. Kean Jr NJ07 | Sold (part) | Sep 30, 2026 | $1K–15K | Oct 30, 2026 |
| Lloyd Doggett TX37 | Bought | Sep 8, 2026 | $1K–15K | Oct 5, 2026 |
| Thomas H. Kean Jr NJ07 | Sold (part) | Aug 27, 2026 | $1K–15K | Sep 12, 2026 |
| Richard Dean Dr McCormick GA06 | Sold | Jul 30, 2026 | $1K–15K | Aug 14, 2026 |
| Thomas H. Kean Jr NJ07 | Sold (part) | Jun 29, 2026 | $1K–15K | Jul 15, 2026 |
| Lloyd Doggett TX37 | Bought | Jun 9, 2026 | $1K–15K | Jul 6, 2026 |
| Thomas H. Kean Jr NJ07 | Sold (part) | Jun 2, 2026 | $1K–15K | Jul 15, 2026 |
| Rohit Khanna CA17 · child | Sold (part) | May 1, 2026 | $1K–15K | Jun 9, 2026 |
| Rohit Khanna CA17 · spouse | Bought | Apr 13, 2026 | $15K–50K | May 11, 2026 |
| Thomas H. Kean Jr NJ07 | Sold (part) | Mar 26, 2026 | $1K–15K | Apr 13, 2026 |
| Richard Dean Dr McCormick GA06 | Sold (part) | Mar 19, 2026 | $1K–15K | Apr 7, 2026 |
| Richard Dean Dr McCormick GA06 | Sold (part) | Mar 19, 2026 | $1K–15K | Apr 7, 2026 |
| Lloyd Doggett TX37 | Bought | Mar 10, 2026 | $1K–15K | Apr 6, 2026 |
| Thomas H. Kean Jr NJ07 | Sold (part) | Jan 23, 2026 | $15K–50K | Feb 19, 2026 |
| Julie Johnson TX32 · joint account | Sold | Dec 18, 2025 | $1K–15K | Jan 15, 2026 |
| Lloyd Doggett TX37 | Bought | Dec 9, 2025 | $1K–15K | Jan 2, 2026 |
| Rohit Khanna CA17 · child | Bought | Dec 5, 2025 | $1K–15K | Jan 6, 2026 |
| Thomas H. Kean Jr NJ07 | Sold (part) | Nov 20, 2025 | $15K–50K | Dec 19, 2025 |
| Julie Johnson TX32 · joint account | Sold (part) | Nov 13, 2025 | $1K–15K | Dec 11, 2025 |
| Rohit Khanna CA17 · child | Bought | Nov 7, 2025 | $15K–50K | Dec 8, 2025 |
| Richard Dean Dr McCormick GA06 | Bought | Nov 5, 2025 | $1K–15K | Dec 9, 2025 |
| Lisa McClain MI09 · spouse | Sold | Oct 31, 2025 | $1K–15K | Nov 21, 2025 |
| Lisa McClain MI09 · spouse | Bought | Oct 30, 2025 | $1K–15K | Nov 21, 2025 |
| Lisa McClain MI09 · spouse | Sold | Oct 30, 2025 | $1K–15K | Nov 21, 2025 |
| Jared Moskowitz FL23 · child | Sold (part) | Oct 10, 2025 | $1K–15K | Nov 22, 2025 |
| Jared Moskowitz FL23 · child | Sold (part) | Oct 10, 2025 | $1K–15K | Nov 22, 2025 |
| Valerie Hoyle OR04 · spouse | Sold | Sep 23, 2025 | $1K–15K | Oct 10, 2025 |
| Kelly Louise Morrison MN03 | Sold (part) | Aug 19, 2025 | $1K–15K | Sep 11, 2025 |
| Julie Johnson TX32 · joint account | Sold (part) | Aug 14, 2025 | $1K–15K | Sep 11, 2025 |
| Lisa McClain MI09 · spouse | Bought | Aug 4, 2025 | $1K–15K | Sep 12, 2025 |
| Thomas H. Kean Jr NJ07 | Sold (part) | Jul 31, 2025 | $15K–50K | Aug 20, 2025 |
| Lisa McClain MI09 · spouse | Sold | Jun 24, 2025 | $1K–15K | Aug 13, 2025 50 days late |
| Lisa McClain MI09 · spouse | Bought | Jun 17, 2025 | $1K–15K | Aug 13, 2025 57 days late |
| Scott Scott Franklin FL18 · joint account | Sold | Jun 16, 2025 | $15K–50K | Jul 14, 2025 |
| Pete Sessions TX17 · spouse | Sold | Jun 12, 2025 | $15K–50K | Jun 21, 2025 |
| Lloyd Doggett TX37 | Bought | Jun 10, 2025 | $1K–15K | Jul 7, 2025 |
| Gilbert Cisneros CA31 | Bought | May 30, 2025 | $15K–50K | Jun 6, 2025 |
| Jefferson Shreve IN06 | Sold | May 12, 2025 | $50K–100K | Jun 22, 2025 |
| Marjorie Taylor Greene GA14 | Bought | May 5, 2025 | $1K–15K | May 6, 2025 |
| Gilbert Cisneros CA31 | Sold (part) | Apr 29, 2025 | $1K–15K | May 6, 2025 |
See a number that looks wrong?